Orserdu™ (elacestrant) – New drug approval
January 27, 2023 - The FDA announced the approval of Menarini Group and Stemline Therapeutics’ Orserdu (elacestrant), for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Top